LLBO Lifeline Biotech Inc (CE)

Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO), a developer of innovative medical technology, announced today that it is now featured on www.stockbully.com. Stockbully.com gives attention to emerging growth companies that seek more exposure in the investment community. Stockbully.com is a multimedia investor relations source that seeks out promising and mostly undiscovered companies in the market place and enables their clients to utilize multimedia marketing to gain exposure via the information highway. �Now that Lifeline Biotechnologies has released the exciting news concerning the filing of their patent, we will work with them to raise awareness of their potentially life-saving product, the First Warning System,� said Adam Ben-Evi, President of StockBully.com. �The company is now doubly focused on finding a suitable strategic partner and we believe that this will be a very exciting time in the development of the company.� �The development of the First Warning System is on the right track, we have filed the patent, and launched our search for a partner to assist us in bringing our unique technology designed to assist in the early detection of breast cancer to market. This is certainly a great time to work with Stockbully.com to get our story out to as many people as possible,� stated Lifeline Biotechnologies, Inc. President and CEO Jim Holmes. About Stockbully.com Stockbully.com differentiates itself from traditional investor relations businesses, in that it strives to take a long-term approach. It nurtures and supports promising emerging companies with the aim of growing and appreciating in value. Through exposure on the Internet, Stockbully.com enables its clients to secure a place in their respective sector. Clients with limited financial means can utilize multimedia marketing via the Internet to gain a competitive edge. For more information, please visit http://www.stockbully.com/. About Lifeline Biotechnologies, Inc: Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System�, which was designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the completion of clinical trials if required, and FDA pre-marketing clearance. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive. Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.